Vanderbilt University School of Medicine

Luther, James Matthew , M.D., M.S.C.I.
Assistant Professor of Medicine
Assistant Professor of Pharmacology

Lab Url: N/A

Phone Number: (615) 936-3420

Email Address:james.luther@vanderbilt.edu

Luther, James's picture

Office Address   Mailing Address

560 Robinson Research Building

560C RRB 37232-6602


Research Keywords
Aldosterone, Mineralocorticoid receptor, Insulin resistance, Insulin secretion, Metabolic syndrome, Hypertension,Diabetes,Heart,Kidney,Pharmacology,Renal biology,Vascular Biology

Research Specialty
Dr. Luther's research focuses on the roler of the renin-angiotensin-aldosterone system on glucose regulation using human and animal models. We are using pharmacologic tools and genetic interruption to investigate the effects on insulin secretion and insulin sensitivity in vivo.

Clinical Research Description
Research in Dr. Luther's lab is focused on the effects of excess aldosterone in the metabolic syndrome, insulin resistance, and diabetes. We perform clinical studies in humans utilizing hyperglycemic clamps and hyperinsulinemic euglycemic clamps to investigate the effects of renin-angiotensin-aldosterone system blockade.

Clinical Interests
My clinical expertise and interest is in the treatment of resistant hypertension and renal disease, with a special interest in primary aldosteronism and secondary causes of hypertension.

Publications
Gilbert, K, Nian, H, Yu, C, Luther, JM, Brown, NJ. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens, 31(4), 820-9, 2013.

Luo, P, Dematteo, A, Wang, Z, Zhu, L, Wang, A, Kim, HS, Pozzi, A, Stafford, JM, Luther, JM. Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia, 56(4), 901-10, 2013.

Gamboa, JL, Pretorius, M, Todd-Tzanetos, DR, Luther, JM, Yu, C, Ikizler, TA, Brown, NJ. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol, 23(2), 334-42, 2012.

Luther, JM, Luo, P, Wang, Z, Cohen, SE, Kim, HS, Fogo, AB, Brown, NJ. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int, , , 2012.

Wang, Z, Hill, S, Luther, JM, Hachey, DL, Schey, KL. Proteomic analysis of urine exosomes by multidimensional protein identification technology (MudPIT). Proteomics, 12(2), 329-38, 2012.

Luther, JM, Brown, NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci, 32(12), 734-9, 2011.

Luther, JM, Luo, P, Kreger, MT, Brissova, M, Dai, C, Whitfield, TT, Kim, HS, Wasserman, DH, Powers, AC, Brown, NJ. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia, 54(8), 2152-63, 2011. PMCID:3216479

Smith, JP, Weller, S, Johnson, B, Nicotera, J, Luther, JM, Haas, DW. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother, 54(3), 1146-51, 2010. PMCID:2825963

Lea, WB, Kwak, ES, Luther, JM, Fowler, SM, Wang, Z, Ma, J, Fogo, AB, Brown, NJ. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int, 75(9), 936-44, 2009. PMCID:2770712

Marney, AM, Ma, J, Luther, JM, Ikizler, TA, Brown, NJ. Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. J Am Soc Nephrol, 20(10), 2246-52, 2009. PMCID:2754101

Luther, JM, Golper, TA. Blood pressure targets in hemodialysis patients. Kidney Int, 73(6), 667-8, 2008.

Luther, JM, Wang, Z, Ma, J, Makhanova, N, Kim, HS, Brown, NJ. Endogenous aldosterone contributes to acute Ang II-stimulated PAI-1 and ppET-1 expression in heart but not aorta. Endocrinology, , , 2008. PMCID:2671907

Pretorius, M, van Guilder, GP, Guzman, RJ, Luther, JM, Brown, NJ. 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women. Hypertension, 51(4), 1190-6, 2008. PMCID:2673569

Pretorius, MM, Gainer, JV, Van Guilder, GP, Coelho, EB, Luther, JM, Fong, P, Rosenbaum, DD, Malave, HA, Yu, C, Ritchie, MD, Vaughan, DE, Brown, NJ. The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance. Clin Pharmacol Ther, 83(1), 122-9, 2008.

Van Guilder, GP, Pretorius, M, Luther, JM, Byrd, JB, Hill, K, Gainer, JV, Brown, NJ. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension, 51(2), 454-9, 2008. PMCID:2581632

Luther, JM, Gainer, JV, Murphey, LJ, Yu, C, Vaughan, DE, Morrow, JD, Brown, NJ. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension, 48(6), 1050-7, 2006.

Murphey, LJ, Malave, HA, Petro, J, Biaggioni, I, Byrne, DW, Vaughan, DE, Luther, JM, Pretorius, M, Brown, NJ. Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. J Pharmacol Exp Ther, 318(3), 1287-92, 2006.

Pretorius, M, Luther, JM, Murphey, LJ, Vaughan, DE, Brown, NJ. Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Arterioscler Thromb Vasc Biol, 25(11), 2435-40, 2005.

Luther, JM, Lakey, DL, Larson, RS, Kallianpur, AR, D''Agata, E, Cousar, JB, Haas, DW. Utility of bone marrow biopsy for rapid diagnosis of febrile illnesses in patients with human immunodeficiency virus infection. South Med J, 93(7), 692-7, 2000.

Spector, JE, Werkhaven, JA, Spector, NC, Huang, S, Page, RN, Baranowski, B, Luther, M, McGehee, B, Reinisch, L. Preservation of function and histologic appearance in the injured glottis with topical mitomycin-C. Laryngoscope, 109(7 Pt 1), 1125-9, 1999.


Postdoctoral Position Available
N/A

Postdoctoral Position Details
N/A

Updated Date
09/24/2013



Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Copyright 2008 Vanderbilt University School of Medicine
The office of Biomedical Research Education & Training All rights reserved.
For questions or problems concerning this page, please submit a help ticket.